Cancer Is Not What You Think: The Genetic Theory Has a Problem

For fifty years the dominant story about cancer has been simple: a gene breaks, a cell goes rogue. Pour billions into finding the broken gene, fix it, cure the disease. But after decades of searching, something unexpected has emerged — the story may be backward.

The Theory Everyone Knows

Ask almost any doctor what causes cancer and you will hear roughly the same answer: mutations in DNA. Certain genes — called tumor suppressors and oncogenes — normally keep cell division under tight control. When those genes mutate, the controls fail. Cells divide without stopping. That is cancer.

This explanation, called the Somatic Mutation Theory, has driven cancer research since the 1970s. It produced the Human Genome Project, the cancer genome atlas, and an enormous class of drugs called targeted therapies — drugs that hunt specific mutations in specific cancers.

The investment has been extraordinary. The logic seemed airtight. And yet — results have been frustrating.

What the Genome Data Actually Showed

When researchers sequenced cancer genomes in detail, they expected to find consistent mutations — the same broken gene driving the same cancer type. What they found instead was chaos.

"Every cancer cell within a single tumor has different mutations," explains Dr. Thomas Seyfried of Boston College, who has spent three decades studying cancer metabolism. "You have thousands of different mutations. There's no consistent genetic signature. There are some cancers that have very few mutations — pediatric medulloblastoma, for example — and yet they're just as aggressive and deadly as cancers with thousands of mutations."

This is a serious problem for the mutation theory. If cancer is caused by specific broken genes, why doesn't every cancer of the same type have the same broken genes? Why do some deadly cancers have almost no mutations at all?

Travis Christofferson, author of Tripping Over the Truth, described the experience of cancer genome researchers as they confronted this: "They expected to find maybe a handful of driver mutations common across cancer types. Instead they found tens of thousands of mutations, most of them different in every patient, every tumor, every cell within the tumor."

The Deeper Problem: Mutations Follow Damage

Here is what makes the metabolic theory compelling to a growing number of researchers: when mitochondria — the cell's energy generators — are damaged, the nucleus becomes unstable. Chromosomes break. DNA copying becomes error-prone. Mutations accumulate.

In this view, mutations are not the cause of cancer. They are a symptom of something happening earlier, in the cell's energy system.

Seyfried frames it this way: "The mitochondria are controlling the genome. When the mitochondria are damaged, the genome becomes unstable and you get all of these downstream mutations. These mutations are a downstream effect of the primary disturbance in energy metabolism."

This is the metabolic theory of cancer in its simplest form: cancer is a disease of energy metabolism. The cell's power plants break down. The cell reverts to an ancient, inefficient backup energy system. And the resulting instability — in chemistry, in signaling, in gene expression — cascades into the uncontrolled growth we call cancer.

Why This Matters for Treatment

The two theories lead to very different strategies.

If cancer is driven by specific mutations, you need specific drugs for each mutation. Since mutations differ in every patient, every tumor, every cell, you end up playing a kind of genetic whack-a-mole — developing targeted therapies against thousands of different variants. This is expensive, often toxic, and frequently temporary (tumors evolve resistance).

If cancer is driven by a universal metabolic dysfunction — specifically, a dependence on glucose and glutamine as fuel — then every cancer shares the same weakness. You do not need to chase thousands of mutations. You target the metabolism that all cancers require to survive.

The next three articles explore the specific evidence behind this idea: what happens inside cancer cells, what a famous set of experiments proved about where cancer control actually lives, and what the two-fuel system means for new treatment approaches.